Ticker: LLY

Eli Lilly

Pharma Healthcare Drug Manufacturers - General
Price 1196.04
Reco Buy Potential 83 Risk 28 Updated 2026-07-27

Forecast impact

positive
Target +15.8% target fill 86.4%
Reaction D5 +0.63% · D10 +2.64% fresh confirmed · market trust
Impact Potential +6 · Risk -3 valid until 2026-08-13

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
Description

Company and Business Model

Eli Lilly is a global healthcare company that focuses on the discovery, development, and commercialization of pharmaceuticals. Its core products include treatments for diabetes, oncology, immunology, and neurodegenerative diseases. Major business segments consist of diabetes care, oncology, and neuroscience, with significant revenue generated from insulin products and cancer therapies. The company is recognized for its innovative drug pipeline and strong market presence in the healthcare sector.

Investment Profile

Eli Lilly's stock is positioned as a balanced investment, appealing to investors seeking moderate growth and some income through dividends. The company demonstrates stable revenue growth and a consistent dividend yield, making it suitable for those looking for a mix of capital appreciation and income. Its established market presence and ongoing product development contribute to a favorable risk-return profile.

Fundamental metrics (experimental) Updated: 2026-07-24
EPS (TTM) — earnings per share for the last 12 months, $
28.20
Revenue QoQ — quarter-over-quarter revenue growth
2.6%
EPS surprise
22.7%
20d volatility
1.6%
Dividend yield
0.7%
last ex-date
2026-08-14
AI recommendation changes
Date Before After Reason
2026-05-18 Hold Buy Strong fundamentals and positive short-term momentum.
2026-05-10 Buy Hold Weak momentum and high risk; mixed analyst signals.
2026-05-08 Buy Solid fundamentals but mixed momentum signals.
Analyst forecasts
Date Analyst Action Target Price Then
2026-07-14 Bernstein Target Raised — → 1385 1185.08
2026-07-13 UBS Target Raised 1250 → 1425 1189.91003
2026-07-13 Guggenheim Target Raised — → 1273 1188.58
News Page 2 of 4
Capital One Honeywell Wells Fargo Intel Johnson & Johnson CVS Health Eli Lilly

Jim Cramer Highlights Buying Opportunities Amid Market Rotation, Focuses on Strong Companies

The recent market downturn, particularly in technology stocks, has prompted a shift towards safer investments, with healthcare and financial sectors showing resilience. Jim Cramer highlights potential buying opportunities in fundamentally strong companies amidst this volatility.
AstraZeneca Novo Nordisk Amgen Pfizer Eli Lilly

Drugmakers Compete to Innovate in Obesity Treatment Market with New GLP-1 Pills and Alternative Therapies

The race among drugmakers to develop innovative obesity treatments is intensifying, with Eli Lilly and Novo Nordisk leading the market while new entrants explore alternative therapies. This competition is crucial as it could reshape the landscape of weight-loss medications and impact pricing and accessibility for patients.
SpaceX Merck Redwire Eli Lilly

The Pharmaceutical Industry Embraces Space: Drug Development in Low Earth Orbit Gains Momentum

The shift of pharmaceutical development to lower Earth orbit represents a significant evolution in the space economy, with the potential to enhance drug formulation and delivery methods. This trend could disrupt traditional pharmaceutical practices and create new investment opportunities as the space economy is projected to exceed $1 trillion by 2040.